These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 8255049)
1. [The effects of the treatment for acute rejection with OKT3 monoclonal antibody treatment on the long-term results of cadaveric kidney transplantation]. Kinukawa T; Hattori R; Ohshima S; Matsuura O; Takeuchi N; Fujita T; Nishiyama N; Ono Y; Sahashi M; Yamada S Nihon Hinyokika Gakkai Zasshi; 1993 Oct; 84(10):1851-6. PubMed ID: 8255049 [TBL] [Abstract][Full Text] [Related]
2. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990 [TBL] [Abstract][Full Text] [Related]
3. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation. Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356 [TBL] [Abstract][Full Text] [Related]
4. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873 [TBL] [Abstract][Full Text] [Related]
5. OKT3 for primary therapy of the first rejection episode in kidney transplants. Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875 [TBL] [Abstract][Full Text] [Related]
6. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115 [TBL] [Abstract][Full Text] [Related]
7. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Norman DJ; Barry JM; Bennett WM; Leone M; Henell K; Funnell B; Hubert B Am J Kidney Dis; 1988 Feb; 11(2):90-3. PubMed ID: 3124611 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants. Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094 [TBL] [Abstract][Full Text] [Related]
10. OKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection. Patschan D; Kribben A; Pietruck F; Lutz J; Binek M; Philipp T; Heemann U; Witzke O Nephron Clin Pract; 2006; 103(3):c94-9. PubMed ID: 16534238 [TBL] [Abstract][Full Text] [Related]
11. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187 [TBL] [Abstract][Full Text] [Related]
12. Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation. Kode R; Fa K; Chowdhury S; Ranganna K; Fyfe B; Stabler S; Damask A; Laftavi MR; Kumar AM; Pankewycz O Clin Transplant; 2003 Aug; 17(4):369-76. PubMed ID: 12868995 [TBL] [Abstract][Full Text] [Related]
13. OKT3 for the treatment of steroid-resistant acute renal allograft rejection. Jogose JT; Bailey RR; Lynn KL; Robson RA; Wells JE Nephron; 1997; 77(3):298-303. PubMed ID: 9375823 [TBL] [Abstract][Full Text] [Related]
14. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function. Cohen DJ; Benvenisty AI; Cianci J; Hardy MA Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507 [TBL] [Abstract][Full Text] [Related]
15. The use of OKT3 in steroid-resistant rejections following cadaveric kidney transplantation. Rosenkranz B; Niebel W; Albrecht K; Wagner K; Philipp T; Eigler FW Transpl Int; 1992; 5 Suppl 1():S112-3. PubMed ID: 14621750 [TBL] [Abstract][Full Text] [Related]
16. Effect of OKT3 in steroid-resistant renal transplant rejection. Petrie JJ; Rigby RJ; Hawley CM; Suranyi MG; Whitby M; Wall D; Hardie IR Transplantation; 1995 Feb; 59(3):347-52. PubMed ID: 7871563 [TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063 [TBL] [Abstract][Full Text] [Related]
18. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection. Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541 [TBL] [Abstract][Full Text] [Related]